PEDF-Derived Peptide Eye Drops for Dry Eye After Cataract Surgery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutic options for dry eye disease (DED) are inadequate in providing effective treatment and prevention, leading to potential corneal damage and vision impairment due to tear film instability and inflammation.
Innovation Solution
Administration of PEDF-derived short peptides (PDSP), such as the 29-mer peptide BRM421, formulated in ophthalmic solutions to treat and prevent DED, particularly in patients with or without cataract, including those post-cataract surgery.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic options (artificial tear, anti-inflammation drugs, analgesics) are used to treat dry eye disease, then some symptoms can be alleviated, but the treatment effectiveness is insufficient and corneal damage may still occur
Solution Approach 1:
The patent changes the molecular parameter of the treatment substance by using PEDF-derived short peptides (20-40 amino acids) instead of conventional drugs. This peptide-based approach modifies the biological activity parameters to achieve more effective treatment while reducing harmful effects on the cornea, as demonstrated by the repair of corneal epithelial cells and inhibition of inflammation cascade.
Solution Approach 2:
The PEDF-derived short peptides act as intermediary substances that mediate between the harmful effects of dry eye disease and the protective response. These peptides inhibit the inflammation cascade and promote cell survival, serving as a protective mediator that prevents corneal damage while alleviating symptoms, rather than directly replacing the damaged tissue or providing only symptomatic relief.
2Reliability
If tear film stability is compromised leading to hyperosmolarity and inflammation, then dry eye symptoms develop, but current treatments cannot effectively prevent the chronic cycle of inflammation and damage
Solution Approach 1:
The PEDF-derived short peptides perform preliminary anti-action by inhibiting the inflammation cascade before it can cause extensive damage to the ocular surface. The peptides prevent the harmful effects of hyperosmolarity and tear film instability from progressing into chronic inflammation and corneal damage, thereby breaking the chronic cycle of injury and repair.
Solution Approach 2:
The patent establishes continuity of useful action through the sustained protective effect of PEDF-derived peptides on the ocular surface. The peptides continuously inhibit inflammation and promote epithelial cell survival, maintaining protection against the chronic cycle of damage and repair, rather than providing only temporary symptomatic relief.
3Reliability
If goblet cells are lost due to tear hyperosmolarity, then mucin secretion decreases and tear film stability is compromised, but current treatments cannot effectively restore or protect goblet cell function
Solution Approach 1:
The PEDF-derived short peptides enable self-service by directly protecting goblet cells and stimulating their function. The peptides promote the survival and differentiation of goblet cells, thereby restoring mucin secretion capabilities without requiring external intervention to replace the lost function. This self-service mechanism addresses the root cause of tear film instability rather than merely compensating for its effects.
Data Source
AI summary
A pharmaceutical composition for use in treating dry eye disease includes a peptide having the amino-acid sequence selected from SEQ ID NO: 1-7. A method for treating dry eye disease, comprising: administering to a subject in need thereof a composition comprising a peptide having the amino-acid sequence selected from SEQ ID NO: 1-7. The dry eye disease is accompanied with cataract. The subject suffers from cataract that has been treated with surgery.